Arshad Husain, MD
Medical Oncology · Crown Point, INNPI 1396856506
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 323 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 8.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,152 and has fallen 81.6% since, to $397 in 2025.
Across 323 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$509
- Johnson & Johnson$447
- Novartis$433
- Amgen$429
- Pfizer$352
- Genentech USA, Inc.$325
- plus $3K from 38 others
What the payments were for
- Food & beverage$5,64596%
- Education$2224%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,867 in reported general payments places this provider in the 60th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 19 | $265,778 |
| BrukinsaZanubrutinib | 13 | $191,501 |
| KisqaliRibociclib Succinate | 13 | $177,544 |
| ErleadaApalutamide | 11 | $167,317 |
| RevlimidLenalidomide | 13 | $157,099 |
| ImbruvicaIbrutinib | 12 | $121,641 |
| VenclextaVenetoclax | 30 | $112,331 |
| XareltoRivaroxaban | 85 | $78,074 |
| EliquisApixaban | 96 | $74,399 |
| Abiraterone Acetate | 18 | $21,942 |
| Anastrozole | 86 | $1,550 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $1,218 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 31 | $879 |
| Ondansetron OdtOndansetron | 53 | $640 |
| Prochlorperazine Maleate | 45 | $619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $260 | $265,77819 claims |
| Johnson & JohnsonErleada, Xarelto | $447 | $245,39196 claims |
| Beigene USA, Inc.Brukinsa | $28 | $191,50113 claims |
| NovartisKisqali | $433 | $177,54413 claims |
| Bristol Myers SquibbRevlimid | $120 | $157,09913 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $238 | $121,64112 claims |
| AbbVieVenclexta | $232 | $112,33130 claims |
| PfizerEliquis | $352 | $74,39996 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $22 | $42930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Crown Point
- Neeru BoseCrown Point$3K
- Mohamed FarhatCrown Point$1K
- Costantine AlbanyLafayette$212K
- Sunil BabuFort Wayne$166K
- Natraj AmmakkanavarIndianapolis$129K
- Rafat AnsariMishawaka$90K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.